适应症:This product is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate cancer (mHSPC), including patients who have not received endocrine therapy or have received endocrine therapy for no more than 3 months.